
Epizyme EPZM
Quarterly report 2022-Q2
added 08-09-2022
Epizyme Cost of Revenue 2011-2026 | EPZM
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 10.5 M | 5.07 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.5 M | 5.07 M | 7.78 M |
Quarterly Cost of Revenue Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 5.17 M | 2.64 M | - | 2 M | 2.49 M | 2.85 M | 1.82 M | 1.61 M | 1.02 M | 614 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.17 M | 614 K | 2.25 M |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
32.2 M | - | 2.43 % | $ 254 M | ||
|
Aeterna Zentaris
AEZS
|
90 K | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
1.36 M | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
27.2 M | - | - | $ 866 M | ||
|
Ascendis Pharma A/S
ASND
|
3.52 M | $ 215.54 | -1.16 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
364 M | $ 19.23 | - | $ 899 M | ||
|
AgeX Therapeutics
AGE
|
40 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
15.3 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
76 K | - | 4.01 % | $ 150 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
1.62 M | $ 0.71 | 17.15 % | $ 8.13 M | ||
|
Adverum Biotechnologies
ADVM
|
100 K | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | ||
|
Exelixis
EXEL
|
83.7 M | $ 41.57 | 0.39 % | $ 11.3 B | ||
|
Ayala Pharmaceuticals
AYLA
|
602 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
20.6 M | $ 2.65 | 0.76 % | $ 16.6 M | ||
|
BioDelivery Sciences International
BDSI
|
23.4 M | - | -4.8 % | $ 255 M | ||
|
CureVac N.V.
CVAC
|
238 M | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
70.7 M | - | 0.49 % | $ 251 B | ||
|
NovaBay Pharmaceuticals
NBY
|
4.37 M | $ 1.5 | 11.94 % | $ 8.73 M | ||
|
AIkido Pharma
AIKI
|
9 K | - | 1.93 % | $ 17.4 M | ||
|
Ionis Pharmaceuticals
IONS
|
15.9 M | $ 69.68 | -1.57 % | $ 11.1 B |